NVS Stock Summary and Trading Ideas (Novartis Ag | NYSE:NVS)

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Novartis Ag trades on the NYSE stock market under the symbol NVS.

As of November 5, 2026, NVS stock price declined to $161.86 with 1,599,893 million shares trading.

NVS has a beta of 0.07, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.00 to the broad based SPY ETF.

NVS has a market cap of $305.69 billion. This is considered a Mega Cap stock.

Last quarter Novartis Ag reported $15 billion in Revenue and $2.46 earnings per share. This fell short of revenue expectation by $-35 million and exceeded earnings estimates by $.22.

In the last 3 years, NVS traded as high as $170.46 and as low as $92.35.

The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, DFAI, DFIC, AVDE, DIHP.

NVS has outperformed the market in the last year with a price return of +33.3% while the SPY ETF gained +10.1%. NVS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.6% and +5.2%, respectively, while the SPY returned -4.4% and -4.8%, respectively.

NVS support price is $162.18 and resistance is $167.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.